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Abstract
Autophagy is a vital basic phenomenon that widely exists in eukaryotic cells. As one type
of programmed cell death, autophagy has gained much more attention in the past few
years. Recent studies suggest that the alterations in autophagy are associated with the
genesis and development of cancers. It can affect cell apoptosis, angiogenesis, and treat‐
ment of tumor. Others’ and our studies have found that some herbal medicines can in‐
duce autophagic cell death in cancer cell models. As herbal medicines are very important
recourses for drug discovery and lead compounds of anticancer drugs, we have summar‐
ized the role of autophagy in inhibitive effect of natural products in cancer cell growth
and metastasis. Finally, we present summary and critical comments on problems in cur‐
rent autophagy study and its future prospect.
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1. Introduction
Autophagy is a highly conserved cellular process that widely exists in eukaryotic cells. As
one type of programmed cell death autophagy has gained great attention in the past few
years. Recent studies suggest that autophagy is associated with the tumoriogenesis and pro‐
gression of cancers. It can affect tumour cell apoptosis, angiogenesis as well as the treatment
outcome of chemotherapeutics. In this chapter, we have summarized the up-to-date re‐
search about cell autophagy, including but not limited to the molecular mechanisms under‐
lying autophagy initiation and the potential targets that autophagy regulates. As many
studies have demonstrated that autophagy plays an important role in cancer initiation and
progression, we also critically reviewed the double-edged sword effect of autophagy in can‐
cer, which is reflected as the cytoprotective autophagy and cytotoxic autophagy. The role of
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autophagy in treatment and resistance of several present conventional anticancer agents is
also discussed in our chapter. As Chinese medicines have a long history in treating cancer in
Asian countries, we also introduced some anticancer natural products from Chinese medi‐
cines that target on autophagy in this chapter.
1.1. Cell autophagy overview through the up-to-date research information
Autophagy means “self-eating” in cells. It is a highly conserved cellular process among
eukaryotes by which long-lived proteins and damaged organelles are packaged in the double-
membrane autophagosomes and transported to lysosomes for degradation. Autophagy is one
type of programmed cell death (PCD) for maintaining cell homeostasis by removing damaged
or abnormal cells. It is a vital basic phenomenon that widely exists in eukaryotic cells, which
has gained much more attention in the recent decades. In the process of autophagy, the
intracellular damaged proteins or organelles are wrapped by the double-membrane structure
autophagy vesicles and sent into the lysosome (for animal) or vacuoles (for yeast and plant)
for further degradation and recycle. As autophagosome belongs to subcellular structures,
normal optical microscope cannot observe it, so transmission electron microscope is needed
for observing the process of autophagy. Generally, the features of phagophore are described
as cup-shaped or crescent-shaped double-membrane or multilayer-membrane structure with
the tendency of wrapping the cytoplasmic components. The characteristics of autophagosomes
are described as double-layer or multilayer vacuole-like structure with cytoplasmic compo‐
nents such as mitochondria, endoplasmic reticulum, and ribosome. Autophagy lysosome is a
monolayer-membrane structure in which the cytoplasmic components undergo degradation.
In the study of the relationship between autophagy and cell death, the presence of a large
number of autophagosomes or autophagic lysosomes were found in the cytoplasm before cell
death, but these cells lack typical apoptosis features such as nuclear pyknosis and karyorhexis
or cell shrinkage and the formation of apoptotic bodies. So this is a new type of programmed
cell death which is different from apoptosis. In order to distinguish between these two types
of cell death, autophagy is also called Type II cell death. In contrast, apoptosis is called Type
I cell death. However, whether autophagy is the direct cause of cell death is still controversial.
Some researchers believe that cell death is caused by the process of autophagy, while some
think that autophagy is not the direct reason for cell death.
As a main intracellular degradation and recycling process, autophagy is important for
maintaining energy homeostasis and cellular remodeling during physiological process. Recent
studies have suggested that alterations in autophagy can affect the genesis and development
in several diseases such as inflammatory disease, heart disease, neurodegenerative disease,
and cancer. A common characteristic in these diseases is a dysfunction of autophagy, which
influenced the susceptibility of programmed cell death. Our knowledge of the functions and
regulation of this programmed cell death pathway has increased substantially in recent years
from studies conducted in Drosophila and yeast, as well as in mammalian cells and tissues.
Generally, there are three types of autophagy: chaperone-mediated autophagy, microautoph‐
agy, and macroautophagy. For chaperone-mediated autophagy, single intracellular proteins
are recognized by a chaperone complex that improves target-motif-governed transport,
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lysosomal membrane binding, migration, and subsequent internalization. For microautopha‐
gy, it utilizes lysosomal limiting membrane invagination, septation, or protrusion to transport
cytoplasmic materials. Macroautophagy is a highly conserved cellular process by which cells
sequester a part of their cytoplasm or organelles into the autophagosomes that will fuse with
lysosomes for degradation and recycling of the enclosed materials. Of the above three types
of autophagy, most of our current studies are focused on macroautophagy (hereafter referred
to as autophagy), which is also the focus of this chapter. Although all these three types of
autophagy differ in the way by which cargo material is transported to the lysosome, they are
similar in the last step of lysosomal protein degradation by hydrolase exposure.
Autophagy is very important for cellular homeostasis. It can promote the catabolism of
denatured proteins or damaged organelles and the elimination of long-lived proteins. In
addition, autophagy is an important adaptive mechanism. It is augmented obviously when
the cells need to cope with certain cellular stresses such as starvation. Recent studies have
demonstrated that autophagy also plays pathological roles sometimes. But the molecular
mechanism of these pathological effects remains unknown.
2. The molecular mechanisms of autophagy
2.1. The initial stage of autophagy
In the initial stage, serine–threonine protein kinase ULK1 promotes the autophagy process.
Autophagy inducers such as the defective nutrition or exposure to some chemotherapy agents
cause dephosphorylation of ULK1; the ULK1 complex consists of ULK1, ATG13, FIP200 and
receives stress signals from mTOR complex 1. When mTORC1 kinase activity is inhibited,
autophagosome formation occurs. ULK1 can activate the phosphorylation of ATG13 and
FIP200 to start the initial stage of autophagy.
2.2. Double-membrane vesicle formation stage of autophagy
In this stage, the Beclin-1–Vps34 complex, which consists of Vps34, Beclin-1, ATG14L, and
Vps15, takes part in the process of vesicle nucleation. Under certain circumstances that induce
autophagy, the dephosphorylated ULK1 complex musters the Beclin-1–Vps34 complex to form
the autophagosome by phosphorylation of Ambra1. In this stage, TRAF6 interacts with
Ambra1, which acts as an E3 ubiquitin ligase for ULK1, which results in stabilization and self-
association of ULK1 by K63 ubiquitination. The dephosphorylated ULK1 complex also
facilitates the activity of the ATG14L-containing Vps34 complex by phosphorylation of
Beclin-1. Furthermore, EGFR and AKT regulate autophagy by phosphorylation of Beclin-1
without the impact of mTORC1. Next, the phosphatidylinositol-3-phosphate created by Vps34
musters an effector protein to facilitate the formation of double-membrane vesicle. The WIPI
protein, which is the transcription product of a member of the ectopic P-granule subset of the
metazoan-specific autophagy gene family, also participates in this stage.
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2.3. Double-membrane vesicle elongation stage of autophagy
ATG proteins participate in the accomplishing of the autophagosome and fit out into two
ubiquitin-like conjugation systems, ATG8 (LC3)–phosphatidylethanolamine and ATG12–
ATG5–ATG16L. For the ATG12–ATG5–ATG16L system, ATG12 is connected to ATG5 by the
synergistic action of ATG107 and ATG. The ATG12–ATG5–ATG16L complex consists of
ATG12–ATG5 and ATG16L by conjugate binding, which takes part in the LC3–phosphatidy‐
lethanolamine conjugation. LC3, created by the ATG4 protease from Pro-LC3, is connected to
phosphatidylethanolamine by ATG3, ATG7, and the ATG12–ATG5–ATG16L complex. After
the above procedure, the lipid-conjugated LC3, which is positioned to the double-membrane
of the autophagosomes, takes part in the formation and elongation of autophagosomes.
2.4. Fusion and degradation stage of autophagy
The captured proteins or organelles waiting for degradation in an engulfing or developing
autophagosome are promoted by autophagy adaptor proteins, or receptors act as a connection.
The complete autophagosomes will fuse with lysosomes to become autolysosomes. In these
structures, the captured organelles and materials will be digested by lysosomal enzymes.
2.5. The final stage of autophagy
In the final stage, an essential component of the mTORC1 complex (mTOR) is reactivated by
nutrients created by the autolysosomes. This process is very important for depressing the
redundant activation of autophagy when the cells are in the periods of starvation. The mTOR
generated from this stage can produce raw materials to form new lysosomes so that the
lysosomes do not reduce during the autophagy procedure.
Figure 1. The process of autophagy
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3. Major autophagy regulation target
cAMP-dependent protein kinases A (PKA), mammalian target of rapamycin complex 1
(MTORC1), and AMP-activated protein kinase (AMPK) are three major kinases for regulating
cell autophagy. These kinases, along with some other molecules such as CAMKK2/CaMKKβ
and TSC1/2, participate in a wide range of intracellular or extracellular signal pathways to
regulate autophagy.
3.1. cAMP-dependent Protein Kinase A (PKA)
When the cell faces some stresses such as absence of growth factors, nutrient starvation,
hypoxia, or endoplasmic reticulum stress, the survival of these cells can be dependent on
autophagy. Recent research has shown that Ras/PKA (cAMP-dependent protein kinase)
signaling pathway was associated with the early stage of autophagy in yeast. The studies
showed that Ras/PKA signaling pathway can suppress the early stage of autophagy in
Saccharomyces cerevisiae cells when faced with nutrient-rich conditions [20]. In mammals, this
suppression is conducted at least partially by the phosphorylation of microtubule-associate
protein 1 light chain 3 by PKA.
3.2. Mammalian Target of Rapamycin Complex 1 (MTORC1)
Studies have shown that MTORC1 is activated by the presence of amino acids. Amino acids
can activate RAG (RAS-GTPases) proteins that regulate MTORC1. Recent research has
demonstrated that in Drosophila melanogaster S2 cells, knockdown of Rag gene inhibited the
activation effect of amino acids on TORC1. The constitutively active (GTP-bound) Rag gene
expression can activate TORC1 without the presence of amino acids signals while expression
of dominant-negative Rag can inhibit the activation effects of amino acids signals on TORC1.
Researchers believe that there is some cross talk between these pathways. For example, PKA
can directly activate MTORC1 and also indirectly activate MTORC1 by suppression of the
AMPK.
3.3. AMP-activated protein Kinase (AMPK)
AMPK can respond to the change of ATP/AMP levels in cells and act as an intracellular ATP/
AMP-sensing kinase. It is also a substrate of PKA and participates in regulating autophagy.
AMP can activate the activity of AMPK, while ATP binding suppresses this kinase activity.
AMPK can phosphorylate the TSC1/2 complex when activated by low ATP/AMP levels. Then,
the phosphorylated TSC1/2 complex can indirectly or directly suppress the activity of
MTORC1. Several studies have also demonstrated that AMPK can induce autophagy by
activating ULK1.
3.4. Other regulating mechanisms
Some studies have proved that ER stress can cause autophagy by leading to Ca2+ concentra‐
tions’ upregulation and inducing calcium/calmodulin-dependent protein kinase 2, beta
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(CAMKK2/CaMKKβ), to activate AMPK [29]. (UPR) signaling also plays an important role in
ER stress-related autophagy. This signal pathway has been proved in both mammals and yeast
models. However, the final results of autophagy in response to ER stress are still not clear.
Some researchers insist that it will improve cell survival while others believe that it may lead
to cell death.
4. The relationship of cell autophagy and cancer
4.1. Autophagy: A double-edged sword in cancer
Recent studies have demonstrated that autophagy plays an important role in cancer initiation
and progression stages. In some studies, autophagy has shown tumor inhibition effect by
inducing autophagic cell death. But some studies have also proved that autophagy can
facilitate cell survival during cancer treatment or other stresses. Many cancer researchers have
recognized that autophagy is a double-edged sword in cancer. Usually, the role of autophagy
in cancer depends on the tumor stage, the tumor genotype and microenvironment, as well as
the type of therapy. For example, some recent studies have found that different kinds of
autophagy-inducing drugs can play different roles in cancer treatment. In one study, the
researchers used TRAIL and Fas ligand to treat cell lines with different autophagic levels
(Modified from: Antioxid Redox Signal. 2014 Jan 20; 20(3): 460–473)
Figure 2. The regulation mechanisms of autophagy
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respectively. These two compounds can both activate the cell death receptors and induce
programmed cell death.
4.2. The cytoprotective autophagy in cancer
Previous studies have confirmed that autophagy can lead to resistance against metabolic stress
and protect tumor cells through recycling organelles or proteins. In a study of Kirsten rat model,
the sarcoma-activating viral oncogene homolog (K-Ras) variations can upregulate autophagy
and facilitate tumor cell survival by autophagy. Some studies also demonstrated that both
radiation therapy and chemotherapeutic agents can lead to autophagy and facilitate tumor cell
survival. Although these studies have proved that the conventional cancer therapy may induce
autophagy and reduce tumor cell apoptosis, no direct evidence has proved that inhibition of
cell autophagy can increase the sensitivity of chemotherapy and radiation for cancer treat‐
ment. So the cytoprotective role by autophagy in cancer still needs more supportive evidence.
If we can prove this cytoprotective form of autophagy in cancer, we can reduce the therapy
resistance by inhibiting tumor cell autophagy during conventional cancer treatment [37].
(Modified from: Semin Cancer Biol. 2013 Aug;23(4):252-61.)
Figure 3. Autophagy: a double-edged sword in cancer
4.3. The cytotoxic and cancer inhibitory autophagy
As we have discussed above, many studies have shown the cytotoxic form of autophagy in
cancer. One study has combined vitamin D with radiation therapy for breast tumor model.
The results showed that autophagy induced by the therapy can facilitate cell death in breast
tumor. According to recent studies on autophagy, the cytotoxic form of autophagy was
generated on directly killing cells by itself or further inducing apoptosis-related cell death.
Some recent studies have also discovered that the autophagy-related genes such as Beclin 1
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can suppress tumor devolvement in both human and mice cells. Further studies demonstrated
that this tumor suppression effect by autophagy was related to the Akt pathway. Some
antitumor agents also have been established with the activity of inducing autophagy-related
cell death and tumor suppression [39]. Autophagy deficiency can induce the accumulation of
the autophagy substrate P62 and promote the tumor growth through the NF-kB pathway. The
deficiency of autophagy-related genes such as Beclin-1, UVRAG, and Bif-1 has been confirmed
in many different tumor types. These findings further strengthen the potential linking between
autophagy and cancer inhibition. Autophagy-related cell death and tumor suppression are
very important in recent anticancer research especially when tumor cells are deficient in
essential apoptotic modulators such as caspases and Bcl-2 family. The cytotoxic and cancer
inhibitory autophagy may be a potential target for developing novel cancer therapy, although
there are still some unsolved problems in this field. In future studies, the molecular mecha‐
nisms of cytotoxic and cancer inhibitory autophagy still need further exploration.
5. Anticancer drug discovery target on autophagy
5.1. Overview of conventional anticancer agent target on autophagy
One of the characteristics of tumor cells is their capacity to escape from apoptosis. Recent
studies have suggested that in some conditions, nonapoptotic cell death can occur in tumor
cells, which may related with autophagy. Although there are few antitumor drugs that target
autophagy in present clinical cancer therapy, many existing antitumor drugs can suppress
tumor growth with more or less connections with autophagy. Some drugs can induce auto‐
phagic cell death directly or indirectly by autophagic apoptosis or necrosis. Recent research
has shown that alkali, vincaleukoblastinum, arsenic trioxide, rapamycin, and vitamin D
derivatives can induce autophagic cell death in some cancer cells; while LAK (lymphokine
activated killer cell) can induce autophagic cell death in T98G and U373MG glioblastoma cell
lines 24–96 hours after the treatment. On the other hand, autophagy can also play a tumor cell
protective role by promoting intracellular material cycle and isolating harmful substances. For
example, conventional anticancer drugs, such as some hormonal agents, and chemotherapy
drugs may induce treatment resistance by autophagy. In this case, combination use of
autophagy inhibitor with these drugs is important for clinical therapy. Recent studies have
found that in particular microenvironment or genetic backgrounds, autophagy can play
cytotoxic or tumor inhibitory roles. Therefore, context-specific autophagy regulations can be
a promising novel therapeutic attempt to facilitate the present available antitumor therapy.
Representative autophagy inducers or inhibitors designed for the purposes of promoting or
inhibiting cancer progression are described in Table 1. Among the present studied autophagy-
based anticancer drugs, some autophagy-modulating agents such as and rapamycin have been
approved for clinical use in cancer management ; thus, autophagy has been established as a
promising therapeutic target in cancer treatment.
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5.2. Anticancer natural products from Chinese medicines target on autophagy
Chinese medicines have a long history in treating cancer in some Asian countries and districts.
It is one of the most popular alternative and complementary medicines used for cancer therapy.
The effect of Chinese medicines on survival and improving the quality of life has been
identified by many basic and clinical studies. Recent research has proved that some of these
natural products from Chinese medicines can induce autophagy in tumor cells, while some of
them can suppress autophagy in cancer. Y. Lao et al. found that oblongifolin C, which is
isolated from the herb Garcinia yunnanensis Hu can improve the antitumor efficiency of nutrient
deprivation by inhibiting autophagy. Normally, cancer cells can resist nutrient deprivation by
inducing autophagy and escaping from cell death, but oblongifolin C can inhibit autophagy
in this circumstance and thus exhibit antitumor effect. M. Chen et al. reported that Ophiopo‐
gonin B, which is isolated from the herb Radix Ophiopogon Japonicus, can suppress cell cycle,
inducing autophagic cell death in lung cancer cells in vitro. M. Pedro et al. and their research
teams found that seven natural prenylated flavones extracted from Chinese medicine herbs
can induce autophagy in MCF-7 cells and suppress tumor cell growth. Honokiol, which is
isolated from the herb Mangnolia officinalis, has been demonstrated with anticancer effect by
inducing autophagic cell death on melanoma cells; further study of mechanisms has confirmed
that the related signal pathways are Notch signaling and AKT/mammalian target of rapamy‐
cin. The herb Syzygium samarangense’s active compound dimethyl cardamonin can inhibit the
growth of colorectal carcinoma HCT116 cells by inducing autophagy; the molecular mecha‐
nism study confirmed that the microtubule-associated protein (LC3)-I-LC3-II is related with
the autophagic cell death by this agent. Law reported that the natural product from herb Alisma
orientale can induce autophagy and cell cycle arrest in cancer cells through clearing cellular
stress; this discovery has been further proved by another research team that also used a Chinese
medicine active compound cucurbitacin B to induce cell autophagy. Research from our lab in
The University of Hong Kong demonstrated that fangchinoline (isolated from Fangji, Stephenia
tetrandra S Moore) can induce autophagic cell death in two human hepatocellular carcinoma
cell lines HepG2 and PLC/PRF/5. Further descriptions of the mechanisms of some isolates from
Chinese medicines targeting on autophagy are presented in Table 1. These natural products
from Chinese medicines are very important sources for cancer treatment, but it still needs more
molecular mechanism studies in the future.
Agent Target Regulation
mechanisms
Tumor type Role in cancer
Rapamycin mTORC1 mTORC1 inhibitors Malignant glioma pro-death




uUrsolic acid* Breast cancer pro-death
INNO-406 BCR-ABL Tyrosine kinase
inhibitors
Chronic myeloid leukemia pro-death









Imatinib Chronic myeloid leukemia pro-survival






Baicalin* Akt Akt inhibitors Bladder cancer cells pro-survival
Honokiol * Malignant melanoma cells pro-death
Fangchinoline* AMPK AMPK activators Hepatocellular carcinoma pro-death
NPI-0052 Proteasome Proteasome inhibitors Ovarian cancer pro-survival
Prostate cancer pro- death
Bortezomib Prostate cancer pro-survival








Pseudolaric acid B* BH3 domain Bcl-2 inhibitors Prostate cancer pro-death
Oridonin* Malignant glioma pro-survival
Z18 Breast cancer pro-death
Oridonin* NF-κB NF-κB inhibitors Colon cancer pro-survival
Silibinin* NF-κB NF-κB activators Multiple cancer pro-death
Etoposide* Topoisomerase II Hepatocellular carcinoma pro-death
3-MA PI3K PI3K inhibitor Colon cancer, esophageal
squamous cell carcinoma
pro-survival
CQ Lysosome Lysosomotropic agents Glioblastoma, colon cancer pro-survival
HCQ Breast cancer pro-survival
Dimethyl cardamonin* (LC3)-I-LC3-II (LC3)-I-LC3-II activator Colorectal carcinoma cells pro-death
* represents natural products from Chinese medicines
(Modified from: Acta Pharmacol Sin. 2013 May; 34(5): 612–624)
Table 1. Representative antitumor agents target on autophagy
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6. Summary: Problems in current autophagy study in cancer and future
prospects
Autophagy is a homeostatic process that is highly conserved across different types of mam‐
malian cells. Sustained and excessive autophagy may lead to cell death and tumor shrinkage.
Autophagy is able to relieve tumor cell from oxidative and nutrient stress during the rapid
expansion of cancer. The mechanisms and the role of autophagy in human cancer are compli‐
cated. Many recent discoveries in basic research have found that targeting autophagy may be
a potential novel therapeutic solution for treating cancer. Technical variations in detecting
autophagy affect data quality, and studies should focus on elaborating the role of autophagy
in deciding cell fate. Although our knowledge on autophagy in cancer research has increased
rapidly in the last few decades, there are still some problems in the current study of autophagy.
How to monitor a dynamic autophagy process with improved technique and method? Why
does autophagy have either tumor protective or inhibitor role at different cancer stages and in
different microenvironments? How does autophagy regulate varies of tumor generation or
inhibition pathways? Would targeting the autophagy-related cancer pathways be a novel
strategy for anticancer therapy? Also, as cancer is a systemic disease, many autophagy-related
cross-talk pathways need to be further studied at a systems level in future research. According
to previous studies, some chemical agents have been proved with the ability of inducing or
suppressing autophagy in vitro, but few in vivo data are available in this field. More in vivo
studies on detecting autophagy in tumor initiation and development are urgently required for
drugs development in current cancer research and wide evidence-based clinical research on
the relationship between autophagy and therapy efficacy are also necessary in future studies.
It was shown in the literature that many anticancer natural compounds and extracts could
initiate autophagy in tumor cells as summarized in this chapter. Natural-products-induced
autophagy could protect tumor cells from apoptotic death in some cases. This is an emerging
issue, and it is necessary to study the role of autophagy in tumor suppressive effect of natural
products.
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